Summit Therapeutics PLC 55336VAL4 Bond

SMMT Stock  USD 18.94  0.26  1.35%   
Summit Therapeutics PLC holds a debt-to-equity ratio of 0.032. At this time, Summit Therapeutics' Long Term Debt To Capitalization is comparatively stable compared to the past year. Total Debt To Capitalization is likely to gain to 0.62 in 2024, whereas Interest Debt Per Share is likely to drop 0.14 in 2024. . Summit Therapeutics' financial risk is the risk to Summit Therapeutics stockholders that is caused by an increase in debt.

Asset vs Debt

Equity vs Debt

Summit Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Summit Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Summit Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Summit Therapeutics' stakeholders.
For most companies, including Summit Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Summit Therapeutics PLC, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Summit Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book
32.3324
Book Value
0.594
Return On Assets
(0.31)
Return On Equity
(0.73)
At this time, Summit Therapeutics' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 110.1 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 11 M in 2024.
  
Check out the analysis of Summit Therapeutics Fundamentals Over Time.
View Bond Profile
Given the importance of Summit Therapeutics' capital structure, the first step in the capital decision process is for the management of Summit Therapeutics to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Summit Therapeutics PLC to issue bonds at a reasonable cost.
Popular NameSummit Therapeutics MPLX LP 52
SpecializationPharmaceuticals, Biotechnology & Life Sciences
Equity ISIN CodeUS86627T1088
Bond Issue ISIN CodeUS55336VAL45
S&P Rating
Others
Maturity Date1st of March 2047
Issuance Date10th of February 2017
Coupon5.2 %
View All Summit Therapeutics Outstanding Bonds

Summit Therapeutics PLC Outstanding Bond Obligations

Understaning Summit Therapeutics Use of Financial Leverage

Summit Therapeutics' financial leverage ratio measures its total debt position, including all of its outstanding liabilities, and compares it to Summit Therapeutics' current equity. If creditors own a majority of Summit Therapeutics' assets, the company is considered highly leveraged. Understanding the composition and structure of Summit Therapeutics' outstanding bonds gives an idea of how risky it is and if it is worth investing in.
Last ReportedProjected for Next Year
Net Debt34.7 M36.4 M
Short and Long Term Debt Total106.1 M111.4 M
Short Term Debt2.8 MM
Long Term Debt100 M109 M
Short and Long Term Debt22.7 M23.9 M
Net Debt To EBITDA 34.64  36.37 
Debt To Equity 1.29  1.35 
Interest Debt Per Share 0.19  0.14 
Debt To Assets 0.49  0.52 
Long Term Debt To Capitalization 0.56  0.79 
Total Debt To Capitalization 0.56  0.62 
Debt Equity Ratio 1.29  1.35 
Debt Ratio 0.49  0.52 
Cash Flow To Debt Ratio(0.77)(0.81)
Please read more on our technical analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Summit Stock Analysis

When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.

What is Financial Leverage?

Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Leverage and Capital Costs

The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.

Benefits of Financial Leverage

Leverage provides the following benefits for companies:
  • Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
  • It provides a variety of financing sources by which the firm can achieve its target earnings.
  • Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.
By borrowing funds, the firm incurs a debt that must be paid. But, this debt is paid in small installments over a relatively long period of time. This frees funds for more immediate use in the stock market. For example, suppose a company can afford a new factory but will be left with negligible free cash. In that case, it may be better to finance the factory and spend the cash on hand on inputs, labor, or even hold a significant portion as a reserve against unforeseen circumstances.

The Risk of Financial Leverage

The most obvious and apparent risk of leverage is that if price changes unexpectedly, the leveraged position can lead to severe losses. For example, imagine a hedge fund seeded by $50 worth of investor money. The hedge fund borrows another $50 and buys an asset worth $100, leading to a leverage ratio of 2:1. For the investor, this is neither good nor bad -- until the asset price changes. If the asset price goes up 10 percent, the investor earns $10 on $50 of capital, a net gain of 20 percent, and is very pleased with the increased gains from the leverage. However, if the asset price crashes unexpectedly, say by 30 percent, the investor loses $30 on $50 of capital, suffering a 60 percent loss. In other words, the effect of leverage is to increase the volatility of returns and increase the effects of a price change on the asset to the bottom line while increasing the chance for profit as well.